Benzinga | Oct 7, 2020 09:02AM EDT

Citigroup Downgrades Eidos Therapeutics to Neutral, Lowers Price Target to $73.26

Citigroup analyst Joel Beatty downgrades Eidos Therapeutics (NASDAQ:EIDX) from Buy to Neutral and lowers the price target from $80 to $73.26.